<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695782</url>
  </required_header>
  <id_info>
    <org_study_id>DCPT221020</org_study_id>
    <nct_id>NCT04695782</nct_id>
  </id_info>
  <brief_title>Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy</brief_title>
  <acronym>ReRad II</acronym>
  <official_title>Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:&#xD;
&#xD;
      A prospective phase II, non-randomized observational study of dose-escalated pencil beam&#xD;
      proton therapy re-irradiation for pelvic recurrences from rectal cancer.&#xD;
&#xD;
      Re-irradiation is either a part of neo-adjuvant treatment or as a definitive treatment&#xD;
      strategy for un-resectable recurrences.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0-resection</measure>
    <time_frame>5-6 years</time_frame>
    <description>Neo-adjuvant treatment: Rate of pathological complete resection (R0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year local control</measure>
    <time_frame>6-7 years</time_frame>
    <description>Definitive treatment: Rate of 1-year local control rates evaluated by CT or MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>6-8 years</time_frame>
    <description>Local re-recurrence determined by imaging 6, 12 and 24 month post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Disease free survival, defined as time from first day of treatment until first documented sign of disease or death from any course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>Overall survival defined as time from first day of treatment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5-7 years</time_frame>
    <description>Toxicity evaluated by NCI-CTCAE v. 5.0 acute and chronic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>5-7 year</time_frame>
    <description>Quality of life assessment by EORTC QLQ-c30, QLQ-CR29, supplementary EORTC items, and LARS score. Acute and chronic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Rectal Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pencil beam proton radiotherapy</intervention_name>
    <description>Doseescalated pencil beam proton Therapy</description>
    <arm_group_label>Definitive arm pencil beam proton therapy: 57.5-65Gy(RBE)/46-52 fx (1.25 per fraction) two daily</arm_group_label>
    <arm_group_label>Neo-adjuvant pencil beam proton therapy: 55 Gy(RBE)/44fx (1.25 Gy per fraction), two daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â€¢ Locally recurrent rectal cancer.&#xD;
&#xD;
               -  Bioptically verified (adenocarcinoma )&#xD;
&#xD;
               -  Available dose plan from primary radiotherapy&#xD;
&#xD;
               -  Previous pelvic RT (&gt;30Gy EQD2)&#xD;
&#xD;
               -  Evaluated in MDT-conferences (Herlev, Aarhus)&#xD;
&#xD;
               -  Age&gt;18 years&#xD;
&#xD;
               -  PS 0-2&#xD;
&#xD;
               -  Adequate organ function&#xD;
&#xD;
               -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-resectable distant metastases (PET-CT)&#xD;
&#xD;
          -  Unable to undergo MRI, PET-CT&#xD;
&#xD;
          -  Inability to attend full course radiotherapy and follow up in the out patient clinic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Camilla Kronborg, MD, PhD</last_name>
    <phone>+45 78450000</phone>
    <email>camkro@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danish Centre for Particle Therapy</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Kronborg, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

